Scarica l'app Stockscreener
77.74
10.61%
7.46
Dopo l'orario di chiusura:
77.00
-0.74
-0.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$70.28
Aprire:
$71.06
Volume 24 ore:
3.83M
Relative Volume:
5.30
Capitalizzazione di mercato:
$4.02B
Reddito:
$379.25M
Utile/perdita netta:
$-77.34M
Rapporto P/E:
-48.22
EPS:
-1.6122
Flusso di cassa netto:
$-27.87M
1 W Prestazione:
+19.60%
1M Prestazione:
+10.37%
6M Prestazione:
+53.03%
1 anno Prestazione:
+89.01%
Intervallo 1D:
$70.76
$79.95
Intervallo di 1 settimana:
$63.23
$79.95
Portata 52W:
$36.88
$79.95
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
77.74 | 3.63B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Will Mirum Pharmaceuticals Inc. stock pay special dividends2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
How Mirum Pharmaceuticals Inc. stock compares to growth peersMarket Growth Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Mirum Pharmaceuticals Surges Following Strategic Moves and Analyst Ratings - timothysykes.com
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsM&A Rumor & High Accuracy Trade Signal Alerts - ulpravda.ru
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval - Investing.com
Mirum Pharmaceuticals: Bluejay Acquisition Boost - StocksToTrade
Mirum Files Patent Suits to Block Livmarli Generics - TipRanks
Mirum secures $68.5 million in private placement ahead of acquisition By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD - Investing.com
Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target - ts2.tech
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Up 8.9% Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Investing News Network
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals announces additional private placement financing with TCGX - marketscreener.com
Mirum secures $68.5 million in private placement ahead of acquisition - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $140.00 - MarketBeat
Mirum Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Can Mirum Pharmaceuticals Inc. stock reach $100 price target2025 Investor Takeaways & Verified Momentum Stock Ideas - DonanımHaber
Mirum Pharmaceuticals stock price target raised to $140 by Citizens - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target to $140 on pipeline confidence - Investing.com Canada
Market Recap: Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryTrade Risk Report & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - ulpravda.ru
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockQuarterly Profit Summary & Low Risk Entry Point Guides - ulpravda.ru
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? - Yahoo Finance
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryGold Moves & Free Fast Gain Swing Trade Alerts - Улправда
Stifel Nicolaus Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Why Mirum Pharmaceuticals Stock is Climbing - TipRanks
Baird lifts Mirum Pharmaceuticals, Inc. (MIRM) price target on Bluejay Therapeutics acquisition - MSN
The week in pharma: action, reaction and insight – week to December 12 - The Pharma Letter
Eventide Asset Management LLC Has $134.22 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by BVF Inc. IL - MarketBeat
Boone Capital Management LLC Has $32.64 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened - MSN
Rx Rundown: Pfizer, Mirum Pharmaceuticals, Novartis and more - Medical Marketing and Media
Mirum Pharmaceuticals stock price target raised to $110 by Raymond James - Investing.com Canada
Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition - Insider Monkey
Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition - Insider Monkey
What is HC Wainwright's Forecast for MIRM FY2025 Earnings? - MarketBeat
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2025 - BioSpace
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback - Yahoo Finance
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Mirum Pharmaceuticals (Nasdaq: MIRM) approves stock option and RSU inducement grants for 8 new hires - Stock Titan
Mirum Pharmaceuticals stock price target raised to $100 by Leerink - Investing.com Canada
Trading Systems Reacting to (MIRM) Volatility - news.stocktradersdaily.com
Baird Maintains Mirum Pharmaceuticals (MIRM) Outperform Recommendation - Nasdaq
Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report - biocentury.com
One Peninsula drug maker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says - marketscreener.com
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):